AstraZeneca's COVID-19 vaccine is 79 percent effective in preventing the disease and does not increase the risk of blood clots, the biotech firm said Monday, following its U.S. Phase III efficiency trials. 

The shot was also 80 percent effective for over 65s, it said. Several countries have advised against administering the jab to older people due to a lack of data among elderly participants in previous trials.